OR WAIT 15 SECS
© 2020 MJH Life Sciences and Applied Clinical Trials Online. All rights reserved.
© 2020 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
August 01, 2004
New standards and research methods aim to provide more useful information on population subgroups.
Dismay over the level of anti-pharma feeling in the EU is not just "crying wolf."
Move away from the "service" model if it means being subservient.
Readers respond to articles and columnists.
Long overlooked as global drug innovators, Japanese pharmaceutical companies are gaining attention for their novel clinical development programs.
Well-planned studies designed to pinpoint additional data are increasingly important as a result of the EU's emphasis on added therapeutic value.
A new, standard-based approach minimizes the delays between discovery of innovative agents and identification of their therapeutic benefit for patients-critical in cancer research.
Arthur L. Caplan, Ph.D., chair of the University of Pennsylvania's Department of Medical Ethics, expressed his frank views about issues that are ailing the drug industry today during his DIA Keynote Address in mid-June.